Recce Pharmaceuticals (ASX: $RCE) Phase I/II Clinical Trial Update

Recce Pharmaceuticals Limited (ASX: $RCE) has received approval from an Independent Safety Committee to increase the dosage of R327 to 4,000mg intravenously over a fast infusion of 30 minutes for its Phase I/II clinical trial targeting urinary tract infection/urosepsis. The company is set to start and complete dosing of 6 subjects in the coming weeks after successfully testing R327 at multiple infusion times and identifying the potential optimum fast infusion time of 30 minutes.

Executive Commentary on R327's Dosage Increase

We're thrilled the independent safety committee has unanimously cleared an increased R327 dose to 4,000mg, over a 30-minute fast I.V. infusion. The high concentration potential to administer a broad spectrum anti-infective underscores the potential of a novel treatment for millions of patients worldwide that suffer from Urinary Tract Infection/Urosepsis each year.

Summary of Recce Pharmaceuticals (ASX: $RCE) Announcement

Recce Pharmaceuticals Limited (ASX: $RCE) has successfully obtained approval from an Independent Safety Committee to increase the dosage of R327 to 4,000mg intravenously over a fast infusion of 30 minutes for its Phase I/II clinical trial targeting urinary tract infection/urosepsis. The company's identification of the potential optimum fast infusion time and the increase to a higher concentration align with regulatory expectations, demonstrating the potential of R327 as a novel treatment for patients suffering from these conditions. The company's ambitions to address urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens through its anti-infective pipeline, including RECCE® 327, highlight its commitment to developing innovative solutions. The successful completion of this human clinical trial is expected to provide valuable insights into the efficacious potential of R327 via I.V. administration, offering hope for patients worldwide. Recce Pharmaceuticals continues to pursue its corporate strategy of developing a New Class of Synthetic Anti-Infectives to meet unmet medical needs and combat antibiotic-resistant superbugs and emerging viral pathogens.